NCT06555783: An ongoing trial by Alkermes, Inc.
This trial is ongoing. It must report results 7 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06555783 |
|---|---|
| Title | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 26, 2024 |
| Completion date | Nov. 11, 2025 |
| Required reporting date | Nov. 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |